Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018).
Xingrui HeXiabin ChenHancheng ZhangTian XieXiang-Yang YePublished in: Expert opinion on therapeutic patents (2019)
As a key component of the JAK-STAT signaling pathway, Tyk2 regulates INFα, IL12, and IL23. Selective inhibition of Tyk2 can provide pharmacological benefits in the treatment of many diseases such as psoriasis, systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), rheumatoid arthritis (RA), cancer, and diabetes. The selectivity against other Jak family subtypes (such as Jak2) is crucial in order to minimize the potential side effects and to maximize the desired pharmacological effects. In this context, this review of recent selective Tyk2 inhibitor patents may prove valid, interesting, and promising within the therapeutic paradigm.
Keyphrases
- systemic lupus erythematosus
- disease activity
- rheumatoid arthritis
- signaling pathway
- type diabetes
- ankylosing spondylitis
- cardiovascular disease
- papillary thyroid
- squamous cell carcinoma
- combination therapy
- ulcerative colitis
- pi k akt
- risk assessment
- induced apoptosis
- insulin resistance
- skeletal muscle
- childhood cancer